Activation of PDGFRA signaling contributes to filamin C-related arrhythmogenic cardiomyopathy.
Suet-Nee ChenChi Keung LamYing-Wooi WanShanshan GaoOlfat A MalakShane Rui ZhaoRaffaella LombardiAmrut V AmbardekarMichael R BristowJoseph ClevelandMarta GigliGianfranco SinagraSharon GrawMatthew R G TaylorJoseph C WuLuisa MestroniPublished in: Science advances (2022)
FLNC truncating mutations ( FLNCtv ) are prevalent causes of inherited dilated cardiomyopathy (DCM), with a high risk of developing arrhythmogenic cardiomyopathy. We investigated the molecular mechanisms of mutant FLNC in the pathogenesis of arrhythmogenic DCM (a-DCM) using patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). We demonstrated that iPSC-CMs from two patients with different FLNCtv mutations displayed arrhythmias and impaired contraction. FLNC ablation induced a similar phenotype, suggesting that FLNCtv are loss-of-function mutations. Coimmunoprecipitation and proteomic analysis identified β-catenin (CTNNB1) as a downstream target. FLNC deficiency induced nuclear translocation of CTNNB1 and subsequently activated the platelet-derived growth factor receptor alpha (PDGFRA) pathway, which were also observed in human hearts with a-DCM and FLNCtv . Treatment with the PDGFRA inhibitor, crenolanib, improved contractile function of patient iPSC-CMs. Collectively, our findings suggest that PDGFRA signaling is implicated in the pathogenesis, and inhibition of this pathway is a potential therapeutic strategy in FLNC-related cardiomyopathies.
Keyphrases
- high glucose
- growth factor
- endothelial cells
- diabetic rats
- induced pluripotent stem cells
- heart failure
- drug induced
- skeletal muscle
- epithelial mesenchymal transition
- smooth muscle
- oxidative stress
- high resolution
- case report
- signaling pathway
- mass spectrometry
- replacement therapy
- combination therapy
- stress induced
- pluripotent stem cells